JP2023542453A - Ｓａｒｓ－ｃｏｖ－２阻害剤 - Google Patents

Ｓａｒｓ－ｃｏｖ－２阻害剤 Download PDF

Info

Publication number
JP2023542453A
JP2023542453A JP2023502638A JP2023502638A JP2023542453A JP 2023542453 A JP2023542453 A JP 2023542453A JP 2023502638 A JP2023502638 A JP 2023502638A JP 2023502638 A JP2023502638 A JP 2023502638A JP 2023542453 A JP2023542453 A JP 2023542453A
Authority
JP
Japan
Prior art keywords
polypeptide
amino acid
seq
acid sequence
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023502638A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022015418A5 (cg-RX-API-DMAC7.html
Inventor
カオ，ロンシン
コベントリー，ブライアン
ゴレシュニク，インナ
ミラー，ローレン
ベイカー，デイビッド
コソドイ，リサ
ボーウェン，ジョン
カーター，ローレン
ケース，ジェームズ，ブレット
ダイアモンド，マイケル
エドマン，ナターシャ
ハント，アンドリュー
ジュウェット，マイケル，クリストファー
オゴハラ，カサンドラ，ジーン
パク，ヤン－ジュン
ラヴィチャンドラン，ラシュミ
スチュアート，ランス，ジョセフ
ヴィースラー，デイビッド
ヴォーゲリ，バスティアン
ウォールズ，アレクサンドラ，シー．
ウー，ケジア
ボイケン，スコット
ウエダ，ジョージ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Washington University in St Louis WUSTL
Original Assignee
Washington University in St Louis WUSTL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Washington University in St Louis WUSTL filed Critical Washington University in St Louis WUSTL
Publication of JP2023542453A publication Critical patent/JP2023542453A/ja
Publication of JPWO2022015418A5 publication Critical patent/JPWO2022015418A5/ja
Priority to JP2025136537A priority Critical patent/JP2025170319A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2023502638A 2020-07-14 2021-05-25 Ｓａｒｓ－ｃｏｖ－２阻害剤 Pending JP2023542453A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025136537A JP2025170319A (ja) 2020-07-14 2025-08-19 Ｓａｒｓ－ｃｏｖ－２阻害剤

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063051474P 2020-07-14 2020-07-14
US63/051,474 2020-07-14
US202063067593P 2020-08-19 2020-08-19
US63/067,593 2020-08-19
PCT/US2021/034069 WO2022015418A1 (en) 2020-07-14 2021-05-25 Sars-cov-2 inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025136537A Division JP2025170319A (ja) 2020-07-14 2025-08-19 Ｓａｒｓ－ｃｏｖ－２阻害剤

Publications (2)

Publication Number Publication Date
JP2023542453A true JP2023542453A (ja) 2023-10-10
JPWO2022015418A5 JPWO2022015418A5 (cg-RX-API-DMAC7.html) 2024-06-03

Family

ID=76808129

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023502638A Pending JP2023542453A (ja) 2020-07-14 2021-05-25 Ｓａｒｓ－ｃｏｖ－２阻害剤
JP2025136537A Pending JP2025170319A (ja) 2020-07-14 2025-08-19 Ｓａｒｓ－ｃｏｖ－２阻害剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025136537A Pending JP2025170319A (ja) 2020-07-14 2025-08-19 Ｓａｒｓ－ｃｏｖ－２阻害剤

Country Status (7)

Country Link
US (1) US20230250134A1 (cg-RX-API-DMAC7.html)
EP (1) EP4182027A1 (cg-RX-API-DMAC7.html)
JP (2) JP2023542453A (cg-RX-API-DMAC7.html)
KR (1) KR20230038485A (cg-RX-API-DMAC7.html)
CN (1) CN116209672A (cg-RX-API-DMAC7.html)
AU (1) AU2021308208A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022015418A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023282281A1 (ja) * 2021-07-07 2023-01-12 国立大学法人東京医科歯科大学 抗ウイルス活性を有するペプチド、当該ペプチドを含む抗ウイルス剤、当該抗ウイルス剤の製造方法
KR20240177843A (ko) * 2023-06-20 2024-12-30 주식회사 엔큐라젠 SARS-CoV-2스파이크 단백질에 특이적으로 결합하는 펩타이드 및 이의 용도
WO2025101453A1 (en) * 2023-11-07 2025-05-15 University Of Washington De novo design of potent minibinder antagonists of il-6r, gp130, and il1-r1

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6900033B2 (en) * 2001-06-04 2005-05-31 Human Genome Sciences, Inc. Methods and compositions for modulating ACE-2 activity

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ZHANG G ET AL.: "The first-in-class peptide binder to the SARS-CoV-2 spike protein", BIORXIV [ONLINE], JPN6025020251, 20 March 2020 (2020-03-20), ISSN: 0005597557 *

Also Published As

Publication number Publication date
JP2025170319A (ja) 2025-11-18
WO2022015418A1 (en) 2022-01-20
CN116209672A (zh) 2023-06-02
US20230250134A1 (en) 2023-08-10
KR20230038485A (ko) 2023-03-20
AU2021308208A1 (en) 2023-01-05
EP4182027A1 (en) 2023-05-24

Similar Documents

Publication Publication Date Title
JP7094103B2 (ja) インフルエンザウイルスワクチンおよびその使用
JP2025170319A (ja) Ｓａｒｓ－ｃｏｖ－２阻害剤
JP6643981B2 (ja) インフルエンザウイルスワクチンおよびその使用
JP6735269B2 (ja) インフルエンザウイルスワクチンおよびその使用
WO2018028635A1 (zh) 一种寨卡病毒人源单克隆抗体及其应用
CN105073196B (zh) 呼吸道合胞病毒f蛋白表位
JP4902352B2 (ja) トランスフォーミング増殖因子β１（ＴＧＦ−β１）との結合能を有するペプチド
JP2022530439A (ja) 組換えインフルエンザ抗原
WO2021170131A1 (zh) 可溶性ace2和融合蛋白，及其应用
CN113785052A (zh) 新重组二胺氧化酶及其治疗以过量组胺为特征的疾病的用途
KR20240012394A (ko) SARS-CoV-2 폴리펩타이드
CA3181996A1 (en) Sars-cov-2 inhibitors
WO2024229151A2 (en) Multimeric coronavirus binding molecules and uses thereof
CN115925892A (zh) 一种抗新型冠状病毒的中和抗体d9及其应用
US10766929B2 (en) De novo designed hemagglutinin binding proteins
CA3153354A1 (en) Computational design of alpha(v) beta (6) integrin binding proteins
JP2022536797A (ja) 炎症性状態を処置するための方法および組成物
JP2022508619A (ja) ニューロメジンペプチドを使用して２型サイトカイン媒介性炎症を低減させる方法
CN115925893B (zh) 一种抗新型冠状病毒的中和抗体d7及其应用
US12098175B2 (en) Peptide inhibitors targeting the CXCL12/HMGB1 interaction and uses thereof
JP7687637B2 (ja) 抗ウイルス活性を有するペプチド、当該ペプチドを含む抗ウイルス剤、当該抗ウイルス剤の製造方法
WO2025101453A1 (en) De novo design of potent minibinder antagonists of il-6r, gp130, and il1-r1
WO2025250851A1 (en) Trivalent pan-sarbecovirus mucosal vaccine constructs and methods of making and using same
WO2023144625A2 (en) Enhanced hace2-based neutralizing agents against sars-cov-2 infection
CN114249802A (zh) 冠状病毒拮抗肽及其应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230323

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230907

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240524

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240524

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250520

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251111